Explore the latest funded projects through our TechAdvance® early-stage technology fund, providing financial support and business expertise to Rutgers faculty and students to advance their promising technologies toward commercialization.
By playing a 5-minute computer game, we designed a computerized system that can screen for clinical depression and predict response to antidepressants in advance with a 95% accuracy. This system builds on research in cognitive neuroscience, applied mathematics, and machine learning.
The application of leukemia inhibitory factor in prevention and treatment of radiation/chemo-induced gut syndrom and GVHD
Biodegradable nanoscaffolds for in vivo drug delivery and stem cell differentiation. This will provide a new treatment for patients suffering from incurable tissue injuries and diseases.
A prototype sprayable chronic wound dressing and healing novel, cost-effective, sprayable antimicrobial formulations and wound dressing products that can prevent biofilm formation for chronic wound care.
Confirmatory diagnostic screening assay for Tick-borne infections in donated blood samples using the patented molecular beacon probe-based multiplex quantitative PCR (qPCR) testing for three tick-borne infections.
A novel sequencing technology to look at mutations in individual sperm to identify the specific mutations that would predispose a father to having children with paternal age-associated disorders.
Our project is involved in the development of a hand-held portable device that is capable of robotically performing venipuncture procedures safely, quickly, and with high first-stick accuracy on a wide range of patient populations.
dNANOSIS is a rapid and reliable nucleic-acid assay to confirm viral infection status, which can be used as point-of-care diagnosis by transplant surgeons and health professionals. dNANOSIS will benefit health outcomes by improving the utilization of viremic organs and applying to mass screening for emerging infectious diseases.
Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disorder worldwide that can progress to steatohepatitis (NASH), the leading reason for liver transplants. In the U.S., about 100 million affected by this disease. The proposed work will investigate a new treatment, using preclinical animal models of NAFLD.